Evidence map›Paper›PMID 12087179›Full record

ArticleNucleic acids research2002

On the epigenetic regulation of the human reelin promoter.

Ying Chen, Rajiv P Sharma, Robert H Costa, Erminio Costa, Dennis R Grayson

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 275 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Genomics in Treatment Development.Advances in neurobiology · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Inhibitors of DNA Methylation.Advances in experimental medicine and biology · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Neuronal DNA Methyltransferases: Epigenetic Mediators between Synaptic Activity and Gene Expression?The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2018
    Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ying ChenPsychiatric Institute, Department of Psychiatry, 1601 West Taylor Street, M/C 912, College of Medicine, University of Illinois, Chicago, IL 60612, USA.
Rajiv P Sharma
Robert H Costa
Erminio Costa
Dennis R Grayson
University of Illinois Chicago · US

Funding

Reelin and GAD67 DownregulationR01MH062090 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI COSTA, ERMINIO · 2001 to 2005
$1.4M
Regulation of the Reelin GeneR01MH062682 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GRAYSON, DENNIS R · 2002 to 2006
$1.3M
NIMH NIH HHS 1R01MH062682-01A2NIMH NIH HHS 5R01MH062090-02NIMH NIH HHS R01 MH062090NIMH NIH HHS R01 MH062682
6 · The paper itself

Abstract

Reln mRNA and protein levels are reduced by approximately 50% in various cortical structures of post-mortem brain from patients diagnosed with schizophrenia or bipolar illness with psychosis. To study mechanisms responsible for this down-regulation, we have analyzed the promoter of the human reelin gene. We show that the reelin promoter directs expression of a reporter construct in multiple human cell types: neuroblastoma cells (SHSY5Y), neuronal precursor cells (NT2), differentiated neurons (hNT) and hepatoma cells (HepG2). Deletion constructs confirmed the presence of multiple elements regulating Reln expression, although the promoter activity is promiscuous, i.e. activity did not correlate with expression of the endogenous gene as reflected in terms of reelin mRNA levels. Co-transfection of the -514 bp human reelin promoter with either Sp1 or Tbr1 demonstrated that these transcription factors activate reporter expression by 6- and 8.5-fold, respectively. Within 400 bp of the RNA start site there are 100 potential CpG targets for DNA methylation. Retinoic acid (RA)-induced differentiation of NT2 cells to hNT neurons was accompanied by increased reelin expression and by the appearance of three DNase I hypersensitive sites 5' to the RNA start site. RA-induced differentiation was also associated with demethylation of the reelin promoter. To test if methylation silenced reelin expression, we methylated the promoter in vitro prior to transfection. In addition, we treated NT2 cells with the methylation inhibitor aza-2'-deoxycytidine and observed a 60-fold increase in reelin mRNA levels. The histone deacetylase inhibitors trichostatin A (TSA) and valproic acid also induced expression of the endogenous reelin promoter, although TSA was considerably more potent. These findings indicate that one determinant responsible for regulating reelin expression is the methylation status of the promoter. Our data also raise the interesting possibility that the down-regulation of reelin expression documented in psychiatric patients might be the consequence of inappropriate promoter hypermethylation.

Indexed as

Base SequenceCell Adhesion Molecules, NeuronalCell DifferentiationCell LineChromatinDeoxycytosine NucleotidesDNA MethylationExtracellular Matrix ProteinsGene Expression RegulationHistone Deacetylase InhibitorsHistone DeacetylasesHumansHydroxamic AcidsLuciferasesMolecular Sequence DataNerve Tissue ProteinsCell Adhesion Molecules, NeuronalChromatinDeoxycytosine NucleotidesdipropylacetamideExtracellular Matrix ProteinsHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsLuciferasesNerve Tissue ProteinsRecombinant Fusion ProteinsReelin ProteinRELN protein, humanRNA, MessengerSerine EndopeptidasesTretinointrichostatin AValproic Acid

Identifiers

PMID12087179
PMCPMC117056
OpenAlexW2095605218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.